Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma
β Scribed by P.N. Mainwaring; H. Atkinson; J. Chang; J. Moore; B.W. Hancock; P.J. Guillou; R. Oskam; M.E. Gore
- Book ID
- 117663848
- Publisher
- Elsevier Science
- Year
- 1997
- Tongue
- English
- Weight
- 585 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Thirty-eight patients with metastatic melanoma were evaluated immunologically prior to chemoimmunotherapy. The assays used included recall antigen skin hypersensitivity; lymphocyte count; nonspecific T, non-T, and K cell lymphocytotoxicity; and T and B cell rosette enumeration. Survival curves were
In patients with stage I Clark's level III and IV malignant melanoma (MM), recurrence rates of 30-60% can be expected after resection of the primary lesion. If metastatic disease could be detected early and treated in such patients, survival might be prolonged. Ninety patients (37 males and 53 femal
Lymphocyte blast transformation of 23 melanoma patients was compared to that of 22 healthy persons after stimulation with the mitogens PHA, ConA, and PWM. Transformation rate of lymphocytes in microcultures was measured following 3H-Thymidin uptake in a Liquid-Scintillation-Counter. Calculations wer